In 1058 patients with inflammatory bowel disease who underwent therapeutic drug monitoring for both infliximab and adalimumab, those who developed antibodies to a first anti‐TNF were more likely to develop antibodies to a second anti‐TNF, irrespective of drug sequence. This evidence concerns the gene TNF and inflammatory bowel disease.